Herbal Mouthrinse for Oral Mucositis Study

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (136 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerradiotherapyradiationheadpatient
  Phrases that lowered it: oralstudyagedweekclinical
• Sponsor's past termination rate: 12.5% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Maximum age: 89 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 8.6% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 18820 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 92554 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 49 (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Primary purpose: supportive care (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design
• Sponsor's past trials: 120 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-induced Mucositis NCT00814359 · started 2009 · scored riskier than 85% of active trials completed
• Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer NCT01066741 · started 2009 · scored riskier than 16% of active trials terminated
• A Mouthwash Medicine for the Reduction or Prevention of Mouth Ulceration Caused by Radiotherapy for Head and Neck Cancer NCT06669390 · started 2023 · scored riskier than 50% of active trials completed
• Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy NCT02229539 · started 2014 · scored riskier than 78% of active trials completed
• Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy NCT02123511 · started 2014 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.